Evidence map›Paper›PMID 23407373›Full record

ArticleJournal of human hypertension2013

Blood pressure and chronic kidney disease progression in a multi-racial cohort: the Multi-Ethnic Study of Atherosclerosis.

G S Bloomfield, S S Yi, B C Astor, H Kramer, S Shea, M G Shlipak, W S Post

Open access · bronzeAbstract readMulticenter Study
In one paragraph

Article in Journal of human hypertension, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 21 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 1 country.

G S BloomfieldDivision of Cardiology, School of Medicine, Duke University, Durham, NC, USA.
S S Yi
B C Astor
H Kramer
S Shea
M G Shlipak
W S Post
Johns Hopkins Medicine · USColumbia University · USDuke University · USJohns Hopkins University · USLoyola University Medical Center · USUniversity of California, San Francisco · US

Funding

Adjunctive Use of Apyrase to Fibrinolytic TherapyR44HL095169 · NHLBI · APT THERAPEUTICS, INC. · PI CHEN, RIDONG · 2012 to 2013
$1.3M
Heart Failure Incidence and Progression in Renal DiseaseR01DK066488 · NIDDK · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI SHLIPAK, MICHAEL G · 2004 to 2008
$633k
Risk Factors for Atherosclerosis among Patients with Heart Failure in KenyaK01TW008407 · FIC · DUKE UNIVERSITY · PI BLOOMFIELD, GERALD SAMUEL · 2011 to 2014
$490k
SUBCLINICAL CARDIOVASCULAR DISEASE COORDINATING CENTER-N01HC95159-268095159N01HC095159 · HC · UNIVERSITY OF WASHINGTON · PI KRONMAL, RICHARD A · 1999 to 2006
$304k
Adjunctive Use of Apyrase to Fibrinolytic TherapyR43HL095169 · NHLBI · APT THERAPEUTICS, INC. · PI CHEN, RIDONG · 2009 to 2009
$226k
SUBCLINICAL CARDIOVASCULAR DISEASE STUDY--EBCT READINGN01HC095169 · HC · LA BIOMED RES INST/ HARBOR UCLA MED CTR · PI DETRANO, ROBERT · 1999 to 2001
$124k
FIC NIH HHS K01 TW008407FIC NIH HHS K01 TW008407-02NHLBI NIH HHS N01 HC095159NHLBI NIH HHS N01 HC095169NHLBI NIH HHS N01-HC-95159NHLBI NIH HHS N01-HC-95169NIDDK NIH HHS R01 DK066488NIDDK NIH HHS R01 DK066488-01
6 · The paper itself

Abstract

The relationship between blood pressure (BP) and kidney function among individuals with chronic kidney disease (CKD) remains controversial. This study evaluated the association between BP and estimated glomerular filtration rate (eGFR) decline among adults with nondiabetic stage 3 CKD. The Multi-Ethnic Study of Atherosclerosis participants with an eGFR 30-59  ml min(-1) per 1.73 m2 at baseline without diabetes were included. Participants were followed over a 5-year period. Kidney function change was determined by annualizing the change in eGFR using cystatin C, creatinine and a combined equation. Risk factors for progression of CKD (defined as a decrease in annualized eGFR>2.5 ml min(-1) per 1.73 m2) were identified using univariate analyses and sequential logistic regression models. There were 220 participants with stage 3 CKD at baseline using cystatin C, 483 participants using creatinine and 381 participants using the combined equation. The median (interquartile range) age of the sample was 74 (68-79) years. The incidence of progression of CKD was 16.8% using cystatin C and 8.9% using creatinine (P=0.002). Systolic BP>140 mm Hg or diastolic BP>90 mm Hg was significantly associated with progression using a cystatin C-based (odds ratio (OR), 2.49; 95% confidence interval (CI), 1.12-5.52) or the combined equation (OR, 2.07; 95% CI, 1.16-3.69), but not when using creatinine after adjustment for covariates. In conclusion, with the inclusion of cystatin C in the eGFR assessment hypertension was an important predictor of CKD progression in a multi-ethnic cohort with stage 3 CKD.

Indexed as

Blood PressureAgedAged, 80 and overAsianBiomarkersBlack or African AmericanChi-Square DistributionCreatinineCystatin CDisease ProgressionFemaleGlomerular Filtration RateHispanic or LatinoHumansHypertensionKidneyBiomarkersCreatinineCST3 protein, humanCystatin C

Identifiers

PMID23407373
PMCPMC3830562
OpenAlexW1969660370

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.